findmyKOL

Eric Yan

Basic profile

Pfizer

ORCIDNone on fileNPI
RegionMenifee, CA · WestSpecialtyNephrologyFocusNephrology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2020Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Eric Yan is a Nephrology physician affiliated with Pfizer. OpenAlex indexes 10 publications with 305 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
10publications

Distinct works indexed by OpenAlex.

305citations

Total citations across indexed works.

7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
17companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

27851 Bradley Rd
Ste 125
Menifee, CA 925862282

Telephone

951-672-7967

Provider last certified this registry record 10 Aug 2021.

View the NPPES registry record

Industry payments

17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    54.1%
    Calcium channel blocker9.2%
    Nifedipine Er64%Amlodipine Besylate36%
    Part D60 patients
    ACE inhibitor7.7%
    Lisinopril88%Benazepril Hcl8%Enalapril Maleate5%
    Part D<11 patients

    + 13 more classes in this area

  • Metabolism & gastrointestinal

    30.4%
    SGLT2 inhibitor14.9%
    Farxiga74%Invokana10%Dapagliflozin9%Jardiance7%
    Part D<11 patients
    GLP-1 receptor agonist7.4%
    Trulicity84%Ozempic16%
    Part D<11 patients

    + 10 more classes in this area

  • Blood & clotting

    7.5%
    Erythropoiesis-stimulating Agent5.2%
    Procrit72%Retacrit28%
    Part D17 patients
    Solutions for parenteral nutrition1.7%
    Calcium Acetate100%
    Part D16 patients

    + 1 more class in this area

Where care is delivered (Part B)35.6% facility · 64.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”